Sermorelin
Sermorelin is a synthetic 29-amino acid peptide analog of the naturally occurring growth hormone-releasing hormone (GHRH 1-29), specifically designed to stimulate endogenous growth hormone (GH) production from the anterior pituitary gland. Originally developed as the biologically active N-terminal fragment of human GHRH, sermorelin represents a physiologically appropriate approach to growth hormone optimization that preserves natural pulsatile secretion patterns and regulatory feedback mechanisms.
This peptide has gained considerable attention in endocrinology and age management medicine for its studied role in treating growth hormone deficiency while maintaining physiological safety through preservation of the body's natural regulatory systems. Sermorelin exhibits excellent bioavailability via subcutaneous administration and stimulates growth hormone release without disrupting natural circadian rhythms or feedback inhibition, making it unique among growth hormone-related therapeutics.
Overview
Sermorelin demonstrates excellent water solubility and rapid absorption following subcutaneous injection. The peptide exhibits high affinity for GHRH receptors on pituitary somatotroph cells and is metabolized primarily through enzymatic degradation. Despite its short plasma half-life, sermorelin's biological effects persist through sustained growth hormone release for several hours post-administration.
Chemical structure & Properties
- Molecular Formula: C149H246N44O42S
- Molecular Weight: 3357.96 Da
- Sequence: N-terminal 29 amino acids of human GHRH (1-29)
- Half-life: 8-12 minutes (rapid plasma clearance)
- Stability: Requires proper refrigeration and handling due to peptide nature
Mechanism of Action
Sermorelin exerts its therapeutic effects through specific stimulation of the growth hormone-releasing hormone receptor pathway:
Areas Investigated in
the Research Literature
Current Clinical Evidence
Safety Profile and Considerations
Regulatory Status and Legal Considerations
Regulatory information current as of 28 August 2026. This is a summary, not legal or medical advice, and status can change.
FDA Status
- Classification: Compounded preparation; no FDA-approved product currently available
- Approval Status: No sermorelin product is currently FDA-approved. Geref was discontinued by the manufacturer in 2008 for commercial reasons, not for safety or efficacy, and the approval lapsed thereafter; the prior treatment approval was pediatric, not adult.
- Indications: None. No FDA-approved indication exists.
- Regulatory Position: Approval withdrawn in 2009; available only as a compounded preparation, not FDA reviewed for safety or efficacy.
Clinical Practice Status
- Endocrinology Guidelines: Not recommended in current endocrine society guidelines for growth hormone deficiency.
- Anti-Aging Medicine: Widely accepted in age management medical practice
- Pediatric Endocrinology: Historically used as a diagnostic agent; no longer an FDA-approved product.
Legal Availability
- Commercial Status: Available only as a compounded preparation; no FDA-approved product
- Market Presence: Available through licensed healthcare providers and specialty pharmacies
- Quality Control: Compounded under 503A/503B pharmacy standards; not subject to FDA pre-market manufacturing approval
- Clinical Use: Used clinically as a compounded preparation under medical supervision
Conclusion
What the evidence supports
Sermorelin is a growth-hormone-releasing hormone analog that stimulates endogenous growth hormone production and was previously available as an FDA-approved product (Geref) for a pediatric indication. No sermorelin product is currently FDA approved; Geref was discontinued in 2008 for commercial reasons and the approval lapsed thereafter. It is now available only as a compounded preparation that has not been FDA reviewed for the uses discussed here, and long-term data for those uses is limited. This page summarizes the published research and nothing further.
SERMORELIN SCIENTIFIC
DATA SUMMARY
About this library
This library is published for education. It summarizes published research on compounds studied in this field. Many have no approved medical use, and several cannot lawfully be compounded in the United States. The presence of a page here does not mean Paragon offers that compound. Nothing on these pages is an offer to treat.
This page is general education about a compound studied in this field. Nothing here is medical advice, a recommendation, or an offer to prescribe or supply. A page appearing in this library does not mean Paragon Sports Medicine offers that compound.
Disclaimer: This information is provided for educational purposes only and does not constitute medical advice. Sermorelin requires prescription and medical supervision. Patients should consult with qualified healthcare providers before considering any growth hormone-related therapy.
Statements on this page have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Many peptides described here are not FDA approved for the uses discussed, and some cannot lawfully be compounded in the United States. Nothing on this page is medical advice or a recommendation for any individual. Whether any therapy is appropriate depends on your history, your laboratory results, and a clinical evaluation. Individual results vary. This page is published for education. Use of this site does not create a physician-patient relationship.